GSK plc Announces EXDENSUR Approval in China
Ticker: GSK · Form: 6-K · Filed: 2026-04-08T08:07:08-04:00
Sentiment: neutral
Topics: regulatory-approval, international-expansion, pharmaceuticals
TL;DR
GSK got EXDENSUR approved in China, big market potential.
AI Summary
GSK plc filed a Form 6-K on April 8, 2026, reporting an approved EXDENSUR for use in China. The filing includes the complete submission text file and details GSK's mailing and business addresses in London, UK.
Why It Matters
This approval signifies a new market entry for GSK's EXDENSUR product, potentially leading to increased revenue and market share in China.
Risk Assessment
Risk Level: low — This is a routine filing announcing regulatory approval, with no immediate financial or operational risks disclosed.
Key Players & Entities
- GSK plc (company) — Filer of the 6-K report
- EXDENSUR (product) — Product approved for use in China
- China (country) — Market where EXDENSUR received approval
- 0001131399 (company_id) — CIK number for GSK plc
FAQ
What is EXDENSUR?
The filing does not specify what EXDENSUR is, only that it has received approval for use in China.
When was the approval granted?
The filing was accepted on April 8, 2026, and the document within (EXDENSUR APPROVED FOR CRSWNP IN CHINA) suggests the approval is recent.
What does 'CRSWNP' stand for in the document name?
The filing does not define the acronym 'CRSWNP'.
What is the significance of a 6-K filing?
A 6-K filing is a report of foreign issuer required by the SEC for companies with securities traded in the US, providing information that the company makes public in its home country.
What is GSK's business address?
GSK's business address is 79 NEW OXFORD STREET, LONDON, United Kingdom WC1A 1DG.
From the Filing
EDGAR Filing Documents for 0001654954-26-003334 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001654954-26-003334 Filing Date 2026-04-08 Accepted 2026-04-08 08:07:08 Documents 1 Period of Report 2026-04-08 Document Format Files Seq Description Document Type Size 1 EXDENSUR APPROVED FOR CRSWNP IN CHINA a5397z.htm 6-K 62476 Complete submission text file 0001654954-26-003334.txt 63731 Mailing Address 79 NEW OXFORD STREET LONDON United Kingdom WC1A 1DG Business Address 79 NEW OXFORD STREET LONDON United Kingdom WC1A 1DG 44 20 8047 5000 GSK plc (Filer) CIK : 0001131399 (see all company filings) EIN. : 000000000 | State of Incorp.: X0 Type: 6-K | Act: 34 | File No.: 001-15170 | Film No.: 26846551 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)